PATENT CLAIM ANALYSIS

Application Number: 16170134
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-02
Patent Classification: ["514", "234200"]

Abstract:
The present invention relates to a certain DPP-4 inhibitor for use in combination with metformin in CKD patients.

Claim (Index 10):
The method of  claim 2 , wherein linagliptin is administered in a total oral daily dose of 5 mg, wherein the 5 mg daily dose is administered as 2.5 mg linagliptin twice daily or 5 mg linagliptin once daily.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 97.0
- Lexical Diversity: 1.05556
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15616974', '15918401', '15354053', '14918727', '14928048']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7251557328111731
- 35 USC 102 Novelty (BERT): 0.5925252786489772
- Combined Prediction Score: 0.7118926873949536
- Mean Citation Score: 371.19762
- Max Citation Score: 489.67908
- Similarity Product: 443.5848685052491

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test